AI주식인사이트AI Stock Insight
C

풍전약품

298060KOSDAQ

52.5 / 100

Reference Date: 2026-10-23

Financial Score22.0 / 40
News Sentiment12.5 / 25
Momentum8.0 / 20
Disclosure10.0 / 15
AI Analysis: the debt ratio is very low with excellent financial health but PER raises overvaluation concerns. Declined 6.6% over the past month, with no recent news.

Company InformationBased on 2025 Annual Report

Business Overview

SCM Life Science is a biotech company that develops high-purity stem cell therapeutics using its proprietary layer separation culture technology. It is conducting clinical trials for treatments targeting chronic graft-versus-host disease, acute pancreatitis, and atopic dermatitis. Additionally, it has launched the dermocosmetic brand 'Iroro,' leveraging CXCL1 protein and hPL cultivation technology, and is expanding globally through international sales agreements.

Number of Employees

25people

Average Salary

37.2M KRW

Score Calculation Basis

Detailed Financial Score

PER
366.67Industry Average 15.000.0Point

24.4x industry avg (risky)

PBR
0.59Industry Average 1.207.0Point

Half of industry avg (excellent)

ROE
0.81Industry Average 8.001.0Point

Well below industry avg

Debt Ratio
7.36Industry Average 100.008.0Point

Half of industry avg (excellent)

Trend 2023~20256.0 / 10 points
Revenue Growth Rate
3.0 / 3

Avg ▲1404.4% (2-year basis)

Operating Profit Growth Rate
3.0 / 3

Avg ▲36.5% (2-year basis)

ROE Trend
0.0 / 4

Avg ROE -59.1% (improving, 3yr)

Detailed News Sentiment

0 totalPositive 0Neutral 0Negative 0

Detailed Momentum

52-week position5.0Point

52w mid range (48%)

Current 2,200Won52-week high 3,70552-week low 764
1-month return2.0Point

1m -6.58% (slight drop)

Volume trend1.0Point

Volume dry-up

Detailed Disclosure

2 totalPositive 0Neutral 2Negative 0
  • Neutral주식등의대량보유상황보고서(약식)2026-09-30
  • Neutral임시주주총회결과2026-09-30